Why do we need partnership Drug procurement is more than "shopping" drugs
Drug procurement is more than "shopping" Procurement Cycle Demand Creation Supplier Agreements Financing Receipt, Storage, Distribution Forecasting Quality Assurance Effective Use Product Procurement Product Selection Monitoring
How we work Open ended partnership, loose network structure Work on concrete problems as opportunities arise or needs become acute: GFATM Supply Chain planning; GPRM; regulatory database, IMAI module; forecasting ARV market; Training in drug supply management for HIV programmes. Work in under-laboured HIV-specific domains: prices of production, data production for strategy development (ex. API) Foster collaboration in and outside WHO based on areas of drug supply chain management.
Results and influence Procurement and supply management plans to support Global Fund PR Strategic information highly valued : GPRM, Regulatory status Strong support from partners for strategic orientation chosen: keep network open, no need for MOUs; focus collaboration on problem solving and practical issues Expectations of partners for WHO work increasing: support creation of national level SM coordination groups, organisation of partners in technical communities, broker collaboration between partners, map TA sources, provide normative leadership, increase visibility and commitment to strengthening supply chain management at country level
Why Collect, consolidate and disseminate strategic information regarding affordability, accessibility, and availability of HIV drugs: In-house Products Global Price Reporting Mechanism - on AMD website API prices -on AMD website Regulatory status database - on AMD website Strategic Information: Global Observatory
Global Price Reporting Mechanism (GPRM) http://www.who.int/hiv/amds/price/hdd/ http://www.who.int/hiv/amds/price/hdd/ Why To improve price transparency on ARV market To inform MoHs, state and non state procurement officers and favour price negotiation To inform WHO management in their strategic decision in advocacy How Collection and disseminate transactional data of ARV drugs prices on the web Produce summary analysis of trend and prices of ARVs (Summary report) Contributors: CHAI, Crown Agents, GFATM, IDA HIV Group, JSI, MSH, UNICEF, UNDP, WHO-CPS, WHO NPO, Mission Pharma, SCMS. Achievements Features and reports improved Number of contributors improved Scope expanded from HIV products to TB, malaria medicines and substitution therapy
API Price and producer database http://www.who.int/hiv/amds/sourcespricesAPI.pdf http://www.who.int/hiv/amds/sourcespricesAPI.pdf Why Improve price transparency and favour price negotiation Anticipate potential shortage in APIs and inform API producers Inform WHO management in their strategic decision for advocacy How Collect and disseminate lowest and highest prices of each API on AMD website Analyse API price trends Contributors: all Generic API producers – contact details on AMD website Achievement Tool and product Refined Updated information Increased number of companies reporting to AMDS
Regulatory status database http://ftp.who.int/htm/AMDS/drugsdatabase.pdf http://ftp.who.int/htm/AMDS/drugsdatabase.pdf WHY Limited access to information on ARV marketing authorizations by countries Inform WHO management team in making strategic decision and advocacy Inform state and non state procurement officers, donation programmes, countries using the GFATM grant on which drug is registered and where How Collect regulatory information and make it available in the public domain Contributors: all R&D and generic ARV producers Achievements Searchable database Cross check information at country level with support from AMD partners
Forecasting of the ARV market Why To avoid global supply shortages of antiretroviral drugs as it happened during the scaling-up efforts. How we took it forward Production of draft ARV forecasts 2007-2008 for discussion with manufacturers Consortium of partners: UNAIDS, UNICEF, PfSCM, USAID, Clinton Foundation, Mexico National Inst of Public Health Approaches: normative and consumption models. Survey 2006: uptake of ARVs in low & middle income countries. Published in AIDS Journal, July 2006
Country Support in Supply Management Rationale PSM constraints are major obstacles in the health system Access to HIV commodities requires wide partnership Several partners at country level work in isolation sometimes in competition Lack of sharing of information/harmonization of practices Two major areas of focus Increase collaboration to strengthen the supply management in program planning and implementation processes (Unicef, TCM, WB, GF, DELIVER, IDAsolution) Support the creation of national PSM coordination groups to achieve integrated national supply chain management systems.
Country support in Supply Management Capacity building for PSM planning, training and TA PSM workshops for national professionals (e.g. IDAsolution, Global Fund) Exchange of information and experience sharing among participants Consultant database in PSM TA to urgent request for PSM support when no other partner is available.
Country support in Supply Management: The Future Increase visibility and commitment of PSM in planning process Collaborate with RCC in RO & CO planning processes to ensure that PSM issues are well addressed Support creation of national PSM coordination groups Map country level presence of partners and their PSM area of work Increase WHO capacity to play its convening role of partners at country level: work with TCM, ROs and COs Foster collaboration for technical support between WHO and the AMDS Network Organizations: Global Fund, SCMS, WB, UNICEF, etc.
Tool Development Reporting and M&E Importance Vertical reporting puts a huge burden on national programmes Lack of clarity at implementing levels of the reporting requirements Harmonized reporting helps decide where to start improving supply chain management system Opportunity High level of consensus that "verticalization" in reporting requirements by donors has gone too far: harmonization needed at country level The need for AMD network partners (esp. PfSCM) to develop/implement a harmonized and M&E PSM system. Partners asked WHO to take this process forward
Tool Development: Reporting and M&E; Handbook of supply management at first-level health care facilities What we did Reporting and M&E of ART-PSM system Get the facts and move towards consensus –JSI, MSH, PfSCM, –Programme experts from Rwanda, Tanzania, Uganda, Vietnam –CHMP, CRS, Global Fund, IDA, PEPFAR/OGAC, UNAIDS, UNICEF, World Bank Develop outline interagency document Constitute a working group on content Next steps Draft ART-PSM M&E document developed Field-test and finalise the document Handbook of supply management at first-level health care facilities Manual published and ready for use
Conclusion AMDS is part of health system strengthening Unit of HIV Department PSM is a wide area requiring strong partnership: AMDS works by fostering partnership among technical institutions working in PSM Major areas of AMDS work to increase access to HIV commodities: Strategic information: GPRM, regulatory status, API, patent (in progress) Forecasting of HIV drug needs Regional and country support including capacity building: support in planning (PSM plans) and training of professionals working in national supply chain management systems. M&E